Novartis Sales Growth Strategy Is DTC Ads, “Cleverly Crafted” Phase IVs
Executive Summary
Novartis is considering expanded use of direct-to-consumer ads based on the positive results of DTC campaigns for Elidel, Zelnorm and Lamisil
You may also be interested in...
Novartis Plans Chronic Constipation Disease Ads Following Zelnorm Approval
Novartis plans to begin a patient-directed disease awareness campaign on chronic constipation in 2005
Novartis Plans Chronic Constipation Disease Ads Following Zelnorm Approval
Novartis plans to begin a patient-directed disease awareness campaign on chronic constipation in 2005
Protopic, Elidel Safety Labeling May Be Reviewed, FDA Tells Pediatric Cmte.
FDA plans to discuss the pediatric safety profile of topical immunosuppressants with Novartis and Fujisawa after an advisory committee recommended stronger warnings about the potential carcinogenicity of Elidel and Protopic